Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592390 | 0.91 | ADRB2 (0.42) | ADRB2OPRK1ADRB1SMYD2 | |
| SCHEMBL3598956 | 0.90 | ADRB2 (0.36) | ADRB2MEN1KMT2ASMYD2 | |
| SCHEMBL3602144 | 0.86 | ADRB2 (0.41) | ADRB2MPOOPRM1OPRD1OPRK1 | |
| SCHEMBL3590992 | 0.81 | ADRB2 (0.50) | ADRB2ADRB1 | |
| SCHEMBL2210578 | 0.80 | ADRB2 (0.68) | ADRB2 | |
| SCHEMBL3598104 | 0.79 | SMYD2 (0.53) | ADRB2MPOOPRM1ADRB1SMYD2 | |
| Trifluoroacetic Acid SCHEMBL2212361 | 0.77 | ADRB2 (0.64) | ADRB2 | |
| SCHEMBL3592197 | 0.76 | ADRB2 (0.45) | ADRB2OPRK1ADRB1 | |
| SCHEMBL3598067 | 0.76 | ADRB2 (0.39) | ADRB2MEN1KMT2AADRB1 | |
| SCHEMBL3597952 | 0.74 | TAAR1 (0.37) | ADRB2MPOTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | ADRB2 18/4885MPO 2829/4885OPRM1 83/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885MPO 2773/4885OPRM1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.